Pharmacokinetic modeling of dynamic contrast‐enhanced MRI of the hand and wrist in rheumatoid arthritis and the response to anti‐tumor necrosis factor‐α therapy

Hodgson, Richard; Connolly, Sylvia; Barnes, Theresa; Eyes, B; Campbell, Robert S.; Moots, Robert J.

doi:10.1002/mrm.21349

Cited by 45 publications

(42 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While for most pulse sequences, this range covers the physiological concentrations found in tumor tissue, it does not comprise the typical blood concentrations encountered when measuring the AIF. Nevertheless many DCE-MRI studies neglect the T 2 *-effect to convert the signal intensity variation into concentration curves as it yields an analytical solution linking a relative signal enhancement to a single CA concentration (8)(9)(10)(11)(12)(13). The most accurate conversion method C num , comprising T 2 *-effects, is more difficult to perform as it requires numerical solution of strongly non-linear equation (4).…”

Section: Discussionmentioning

confidence: 99%

“…Our C fo -expression, comprising a first order correction for T 2 *-relaxation, combines the simplicity of the T 2 *-neglecting method, with an accuracy that matches the numerical method for CA concentrations up to 45-50% of C max . In tumor tissue, C fo can be regarded as identical to the numerical method, whereas for three pulse sequences under consideration (12,13,17), blood concentrations up to 10 mM can be calculated with 5% accuracy. For the pulse sequence of Padhani et al (11), the 5% accuracy limit is at 5.6 mM as a consequence of the lower maximal concentration.…”

Section: Discussionmentioning

confidence: 99%

“…Several authors assumed a linear relationship between the relative signal enhancement and the CA concentration (2,5,6), which causes severe error in kinetic parameter estimation (7). Currently, many authors use a nonlinear method as described by Dale et al (8) or by Zhu et al (9) in which T 2 *-relaxation of the MR-signal, caused by the presence of the CA, is neglected (10)(11)(12)(13). The advantage of this approach is that an analytical solution exists, linking a measured signal intensity to a single concentration.…”

mentioning

confidence: 99%

See 2 more Smart Citations

First order correction for T₂*‐relaxation in determining contrast agent concentration from spoiled gradient echo pulse sequence signal intensity

Naeyer

Debergh

Deene

et al. 2011

Magnetic Resonance Imaging

View full text Add to dashboard Cite

Purpose: To investigate the accuracy of a method neglecting T 2 *-relaxation, for the conversion of spoiled gradient echo pulse sequence signal intensity to contrast agent (CA) concentration, in dynamic contrast enhanced MRI studies. In addition a new closed form conversion expression is proposed that accounts for a first order approximation of T 2 *-relaxation. Materials and Methods:The accuracy of both conversion methods is compared theoretically by means of simulations for four pulse sequences from literature. Both methods are tested in vivo against the numerical conversion method for measuring the arterial input function in mice.Results: Simulations show that the T 2 *-neglecting method underestimates typical tissue CA concentrations (0 mM to 2 mM) up to 6%, while the errors for arterial concentrations (0 mM to 10 mM) range up to 43%. The results from our first order method are numerically indistinguishable from the simulation input values in tumor tissue, while for arterial concentrations the error is reduced up to a factor 10. In vivo, peak Gd-DOTA concentration is underestimated up to 14% with the T 2 *-neglecting method and up to 0.9% with our first order method. Conclusion:Our conversion method reduces the underestimation of CA concentration severely in a broad physiological concentration range and is easy to perform in any clinical setting.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

First order correction for T₂*‐relaxation in determining contrast agent concentration from spoiled gradient echo pulse sequence signal intensity

Naeyer

Debergh

Deene

et al. 2011

Magnetic Resonance Imaging

View full text Add to dashboard Cite

show abstract

“…For patients undergoing treatment, scoring systems that evaluate the features of RA from MRI show great potential for monitoring response to therapy (85). Lastly, new MRI methods, such measurement of apparent diffusion coefficient (ADC) and pharmacokinetic modeling of Gadolinium enhancement and washout, offer quantitative metrics to more precisely study RA pathogenesis (86).…”

Section: Rheumatoid Arthritis (Ra)mentioning

confidence: 99%

Potential of PET-MRI for imaging of non-oncologic musculoskeletal disease

Kogan

Fan

Gold

2016

Quant. Imaging Med. Surg.

View full text Add to dashboard Cite

Early detection of musculoskeletal disease leads to improved therapies and patient outcomes, and would benefit greatly from imaging at the cellular and molecular level. As it becomes clear that assessment of multiple tissues and functional processes are often necessary to study the complex pathogenesis of musculoskeletal disorders, the role of multi-modality molecular imaging becomes increasingly important.New positron emission tomography-magnetic resonance imaging (PET-MRI) systems offer to combine high-resolution MRI with simultaneous molecular information from PET to study the multifaceted processes involved in numerous musculoskeletal disorders. In this article, we aim to outline the potential clinical utility of hybrid PET-MRI to these non-oncologic musculoskeletal diseases. We summarize current applications of PET molecular imaging in osteoarthritis (OA), rheumatoid arthritis (RA), metabolic bone diseases and neuropathic peripheral pain. Advanced MRI approaches that reveal biochemical and functional information offer complementary assessment in soft tissues. Additionally, we discuss technical considerations for hybrid PET-MR imaging including MR attenuation correction, workflow, radiation dose, and quantification.

show abstract

“…However, recent software improvements, providing more automated methods, potentially increase assessment speed and reproducibility [103][104][105][106][107]. This encourages the reappraisal of the usefulness of such quantitative methods.…”

Section: Monitoring Disease Activity and Structural Damagementioning

confidence: 99%

The impact of MRI on the clinical management of inflammatory arthritides

et al. 2011

View full text Add to dashboard Cite

In the past two decades, MRI has gained a major role in research and clinical management of patients with inflammatory arthritides, particularly in spondyloarthritis (SpA), rheumatoid arthritis (RA), and osteoarthritis (OA). MRI is regarded as the most sensitive imaging modality for detecting early SpA in young patients with inflammatory back pain and normal radiographs of the sacroiliac joints. The recently published Assessment of SpondyloArthritis International Society classification criteria for axial SpA include for the first time a positive MRI demonstrating sacroiliitis as an imaging criterion indicative of SpA together with at least one clinical feature of SpA. Recent data show that systematic assessment of sacroiliitis displayed on MRI has much greater diagnostic utility than previously reported and highlight the diagnostic relevance of structural lesions. In RA, MRI has predictive value for the development of disease in new onset undifferentiated arthritis, and MR pathology at disease onset is a highly significant predictor of radiographic erosions. Consequently MRI has been credited with an important role in the new ACR/EULAR 2010 classification criteria for RA. In OA, bone marrow edema (BME) and synovitis may serve as biomarkers in interventional trials. Treatment interventions targeting BME and synovitis observed on MRI in inflammatory arthritides may have a disease-modifying effect as these lesions are potentially reversible and have been shown to be associated with structural progression. Research should focus on the prognostic significance of MRI lesions in larger cohorts and whether adding MRI to routine care improves clinical and radiographic outcome in patients with inflammatory arthritides.

show abstract

Pharmacokinetic modeling of dynamic contrast‐enhanced MRI of the hand and wrist in rheumatoid arthritis and the response to anti‐tumor necrosis factor‐α therapy

Abstract: Dynamic contrast-enhanced MRI (DCE-MRI

Cited by 45 publications

References 43 publications

First order correction for T₂*‐relaxation in determining contrast agent concentration from spoiled gradient echo pulse sequence signal intensity

First order correction for T₂*‐relaxation in determining contrast agent concentration from spoiled gradient echo pulse sequence signal intensity

Potential of PET-MRI for imaging of non-oncologic musculoskeletal disease

The impact of MRI on the clinical management of inflammatory arthritides

Contact Info

Product

Resources

About

Pharmacokinetic modeling of dynamic contrast‐enhanced MRI of the hand and wrist in rheumatoid arthritis and the response to anti‐tumor necrosis factor‐α therapy

Abstract: Dynamic contrast-enhanced MRI (DCE-MRI

Cited by 45 publications

References 43 publications

First order correction for T2*‐relaxation in determining contrast agent concentration from spoiled gradient echo pulse sequence signal intensity

First order correction for T2*‐relaxation in determining contrast agent concentration from spoiled gradient echo pulse sequence signal intensity

Potential of PET-MRI for imaging of non-oncologic musculoskeletal disease

The impact of MRI on the clinical management of inflammatory arthritides

Contact Info

Product

Resources

About

First order correction for T₂*‐relaxation in determining contrast agent concentration from spoiled gradient echo pulse sequence signal intensity

First order correction for T₂*‐relaxation in determining contrast agent concentration from spoiled gradient echo pulse sequence signal intensity